Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates
Key facts
- Where
- Prague, CsehországSee the site
- Phase
- 4. fázis
Where in Csehország
- Institute for Clinical and Experimental MedicinePrague, CsehországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute For Clinical And Experimental Medicine
- Trial code
- EU 2026-526044-12-00
- Record updated
- 2026. március 18.
- Original description
To evaluate the efficacy and safety of pharmacological obesity treatment (BMI ≥ 30) in liver transplant candidates.Read full original descriptionShow less
To evaluate the efficacy and safety of pharmacological obesity treatment (BMI ≥ 30) in liver transplant candidates.
Inclusion: Liver transplant candidate undergoing pre-transplant evaluation (inpatient or outpatient) at the Department of Hepatogastroenterology, aged ≥18 years; BMI ≥ 30, or BMI ≥ 33 in case of significant fluid retention (edema of lower extremities, ascites, hydrothorax; for large ascites/hydrothorax, BMI will be evaluated after evacuation puncture); Clinically stable (patient is at home under outpatient follow-up or hospitalized on a standard ward without clinical or laboratory signs of significant deterioration or complications); Signed informed consent.
Exclusion: Combined liver-kidney transplantation; Sarcopenia according to pre-transplant CT; Pregnancy (pre-enrollment assessment includes a pregnancy test; women of childbearing potential must agree to use highly effective contraception — hormonal or barrier methods, or abstinence; highly effective methods are defined as those with failure rate <1% per year with correct and consistent use); History of acute or chronic pancreatitis; Polycystic liver disease; Type 1 diabetes mellitus; Liver malignancy outside Milan criteria (Milan-out, Klatskin tumor, colorectal carcinoma metastases, NET metastases); Unstable clinical condition or unplanned hospitalization due to significant deterioration or complication; Hepatic encephalopathy; Refractory ascites/hydrothorax (≥2 evacuation procedures in the last 2 months); Spontaneous weight loss (≥5% in the past 6 months, not due to diuretic or evacuation treatment); Inability to perform physical activity (walking 30 min/day).